(VIANEWS) – ODFJELL DRILLING (ODL.OL), RYANAIR HOLD. PLC (RYA.IR), PROTECTOR FORSIKRG (PROT.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. ODFJELL DRILLING (ODL.OL)
997.7% sales growth and 18.04% return on equity
Odfjell Drilling Ltd. owns and operates mobile offshore drilling units primarily in Norway and Namibia. The company operates through Own Fleet and External Fleet segments. It also offers management services to other owners of drilling units, such as operational management, regulatory requirements management, marketing, contract negotiations and client relations, and operation and mobilization preparation services. The company was founded in 1914 and is headquartered in Aberdeen, the United Kingdom. Odfjell Drilling Ltd. is a subsidiary of Odfjell Partners Holding Ltd.
Earnings Per Share
As for profitability, ODFJELL DRILLING has a trailing twelve months EPS of kr10.59.
PE Ratio
ODFJELL DRILLING has a trailing twelve months price to earnings ratio of 5.01. Meaning, the purchaser of the share is investing kr5.01 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.04%.
More news about ODFJELL DRILLING.
2. RYANAIR HOLD. PLC (RYA.IR)
38.7% sales growth and 23.1% return on equity
Ryanair Holdings plc, together with its subsidiaries, provides scheduled-passenger airline services in Ireland, the United Kingdom, Spain, Italy, and internationally. The company is also involved in the provision of various ancillary services, such as non-flight scheduled and Internet-related services, as well as in-flight sale of beverages, food, duty-free, and merchandise; and markets car hire, travel insurance, and accommodation services through its website and mobile app. Furter, it offers aircraft and passenger handling, ticketing, and maintenance and repair services; and markets car parking, fast-track, airport transfers, attractions, and activities on its website and mobile app, as well as sells gift vouchers. The company was incorporated in 1996 and is headquartered in Swords, Ireland.
Earnings Per Share
As for profitability, RYANAIR HOLD. PLC has a trailing twelve months EPS of €1.41.
PE Ratio
RYANAIR HOLD. PLC has a trailing twelve months price to earnings ratio of 10.6. Meaning, the purchaser of the share is investing €10.6 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.1%.
Sales Growth
RYANAIR HOLD. PLC’s sales growth for the next quarter is 38.7%.
More news about RYANAIR HOLD. PLC.
3. PROTECTOR FORSIKRG (PROT.OL)
8.1% sales growth and 31.31% return on equity
Protector Forsikring ASA, operates as a non-life insurance company, provides various insurance products to the commercial and public sectors, and the grouped insurance schemes markets in Norway, Denmark, Sweden, the United Kingdom, and Finland. It operates in Commercial Lines of Business and Public Lines of Business segments. The company offers personal insurance, including personal and collective accident, critical illness, group life, health, and travel insurance; motor insurance; property insurance; and liability insurance. It sells its products through insurance brokers and agents. Protector Forsikring ASA was founded in 2003 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, PROTECTOR FORSIKRG has a trailing twelve months EPS of kr16.55.
PE Ratio
PROTECTOR FORSIKRG has a trailing twelve months price to earnings ratio of 13.32. Meaning, the purchaser of the share is investing kr13.32 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.31%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 3564.3% and a drop 48.2% for the next.
Sales Growth
PROTECTOR FORSIKRG’s sales growth is 18.1% for the ongoing quarter and 8.1% for the next.
Yearly Top and Bottom Value
PROTECTOR FORSIKRG’s stock is valued at kr220.50 at 22:20 EST, way under its 52-week high of kr265.00 and way higher than its 52-week low of kr160.00.
More news about PROTECTOR FORSIKRG.
4. SANOFI (SAN.PA)
7.4% sales growth and 5.82% return on equity
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €4.3.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 21.15. Meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.82%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 13, 2024, the estimated forward annual dividend rate is 3.76 and the estimated forward annual dividend yield is 3.81%.
More news about SANOFI.
